AGEN1307

AGEN1307 is a human monoclonal antibody that targets TIGIT (T cell immunoglobulin and ITIM domain) and is designed as a checkpoint inhibitor for cancer immunotherapy. Its mechanism of action includes blockade of TIGIT, resulting in T-cell stimulation, and it features an Fc-engineered region to enhance antibody-dependent cellular cytotoxicity (ADCC) through increased Fcγ receptor binding. The drug is intended to promote anti-tumor immune responses by both inhibiting TIGIT-mediated suppression of T cells and enabling immune cell–mediated cytotoxicity against tumor cells. Developed by Agenus, AGEN1307 is classified as an antineoplastic monoclonal antibody and immunotherapeutic agent. Its current status is preclinical, with no reported clinical or marketed indications[1][3][5][9][13][15].

Other names

AGEN1307AGEN-1307AGEN 1307AGEN 1327AGEN1327AGEN-1327